Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays

Article English OPEN
Rezende, Vinicius; Bendit,Israel; Chamone,; Rivellis,; Novaes,Mafalda;
(2013)
  • Publisher: Dove Press
  • Journal: Drug Design, Development and Therapy,volume 7,pages699-710 (issn: 1177-8881, eissn: 1177-8881)
  • Related identifiers: doi: 10.2147/DDDT.S42902, pmc: PMC3739544
  • Subject: development | high-performance liquid chromatography-mass spectrometry | imatinib | Drug Design, Development and Therapy | Methodology | therapeutic drug monitoring | validation

Vinicius Marcondes Rezende,1 Ariane Rivellis,1 Mafalda Megumi Yoshinaga Novaes,1 Dalton de Alencar Fisher Chamone,2 Israel Bendit1,21Laboratory of Tumor Biology, 2Department of Hematology, School of Medicine, University of São Paulo, São Paulo, Bra... View more
  • References (27)
    27 references, page 1 of 3

    1. Druker BJ, Guilhot FO, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.

    2. Titier K, Picard S, Ducint D, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2005;27(5):634-640.

    3. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol. 2001;28(5 Suppl 7):9-18.

    4. Guilhot F, Hughes T, Cortes J, et al. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 2012;97(5):731-738.

    5. Awidi A, Salem II, Najib N, Mefleh R, Tarawneh B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods comparison. Leuk Res. 2010;34(6):714-717.

    6. Guilhot F, Roy L, Tomowiak C. Current treatment strategies in chronic myeloid leukemia. Curr Opin Hematol. 2012;19(2):102-109.

    7. Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791(1-2):39-44.

    8. Mičová K, Friedecký D, Faber E, Polýnková A, Adam T. Flow injection analysis vs ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Clin Chim Acta. 2010;411(23-24):1957-1962.

    9. Roth O, Spreux-Varoquaux O, Bouchet S, et al. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS/MS. Clin Chim Acta. 2010; 411(3-4):140-146.

    10. Davies A, Hayes AK, Knight K, Watmough SJ, Pirmohamed M, Clark RE. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res. 2010;34(6):702-707.

  • Metrics
    No metrics available
Share - Bookmark